Project Grant R21AA031146
Award Date
9/1/23
Completion Date
8/31/25
Dollars Obligated
$857K
Federal Agency
National Institute on Alcohol Abuse and Alcoholism
Federal Grant Program
93.273
Assistance Type
Project Grant
Place of Performance
Aurora, CO 80045, USA
Similar Awards
This federal Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273) grant program, provides $211,247 to conduct a Phase II randomized trial of the drug tirzepatide (brand name Zepbound) in adults with co-occurring alcohol use disorder and overweight/obesity. The aim is to evaluate the efficacy of this dual GLP-1/GIP receptor agonist in reducing alcohol consumption and improving weight and cardiometabolic outcomes...
This $545,282 Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273) federal grant program, aims to study the neural mechanisms associated with cognitive reappraisal and alcohol cue reactivity in individuals with alcohol use disorder (AUD) during early abstinence. The primary objectives are to: 1) determine how neural mechanisms related to reappraisal and alcohol cue-reactivity change across early abstinence...
This $673,500 Project Grant from the National Institutes of Health's National Institute on Alcohol Abuse and Alcoholism will fund Amygdala Neurosciences, Inc. to develop new, potent, selective, and reversible inhibitors of aldehyde dehydrogenase 2 (ALDH2) for the treatment of alcohol use disorder. The goal is to implement an innovative screening technology to discover novel compounds that reduce craving and alcohol consumption by selectively inhibiting ALDH2 in a reversible manner, avoiding...
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $581,869 Project Grant under the Alcohol Research Programs (CFDA 93.273) to The University of Kentucky Research Foundation. The purpose of this 4-year project, commencing on Aug 1, 2024, is to conduct a rigorous crossover study translating preclinical findings on glucocorticoid receptor (GR) antagonism to humans with alcohol use disorder (AUD). Using the selective GR antagonist PT150, the study will assess its effects on...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $702,965 to the University of Texas Health Science Center at Houston (UTHealth) from June 15, 2025 through February 28, 2029. The primary objective is to conduct a pilot study to evaluate the potential of the medication semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), as a treatment for cocaine use disorder (CUD). The multimodal...
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $999,393 Cooperative Agreement under the Alcohol Research Programs (CFDA 93.273) to Stress Therapeutics, Inc. on May 15, 2025. The purpose of this Phase I SBIR grant is to initiate investigational new drug (IND)-enabling studies for an innovative first-in-class therapeutic candidate aimed at chronic management of pathological hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis for the treatment of alcohol use...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $385,000.00 to Loyola University of Chicago's Health Sciences Campus to conduct a comprehensive analysis of integrated treatment approaches for patients with co-occurring opioid use disorder (OUD) and alcohol use disorder (AUD). The research aims to assess the effectiveness of integrated treatment regimens, including first-line OUD and AUD...
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $667,313 Project Grant under the Alcohol Research Programs (CFDA 93.273) to the University of Oklahoma Health Sciences Center to conduct a randomized controlled trial evaluating the efficacy of a smartphone-based intervention to reduce drinking among adults experiencing homelessness. The primary objective is to assess the effects of the "SMART-T Alcohol" intervention on reducing alcohol consumption and...
This federal Project Grant award of $366,406 from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) will support the development of a novel human laboratory paradigm to model the ability to resist drinking and heavy drinking for alcohol use disorder (AUD) medication screening. The project aims to adapt procedures from successful "ability to resist" smoking models to develop two versions of an "ability to resist"...
This is a Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) federal grant program. The $731,258 award aims to examine the efficacy and underlying mechanisms of guanfacine for treating alcohol use disorder (AUD) in women using a telehealth approach. The grant will fund a 12-week, multi-site clinical trial with 130 female participants recruited across the primary site at Indiana University and the secondary...